Predictive Value Of Plasma Tumor Mutation Burden (Tmb) In The Cctg Pa.7 Trial: Gemcitabine (Gem) And Nab-Paclitaxel (Nab-P) Vs. Gem, Nab-P, Durvalumab (D) And Tremelimumab (T) As First Line Therapy In Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac).
JOURNAL OF CLINICAL ONCOLOGY（2021）
摘要
411Background: PA.7 evaluated whether combining PD-L1 and CTLA-4 inhibition with GEM and Nab-P increases efficacy as first line therapy in mPDAC. High TMB is associated with immunotherapy sensitivi...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要